PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19846942-6 2009 Doxycycline (5 microg/ml) below the cytotoxic level suppressed endogenous and paclitaxel-induced IL-8 expression. Paclitaxel 78-88 C-X-C motif chemokine ligand 8 Homo sapiens 97-101 19826413-8 2009 In MyD88(+) SCOV3 cells, LPS or PTX binding to TLR4 induced IRAK4 activation and cJun phosphorylation, activated the NF-kappaB pathway and promoted interleukin (IL)-8, IL-6, vascular endothelial growth factor and monocyte chemotactic protein-1 production and resistance to drug-induced apoptosis. Paclitaxel 32-35 C-X-C motif chemokine ligand 8 Homo sapiens 148-166 21742513-0 2011 Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Paclitaxel 60-70 C-X-C motif chemokine ligand 8 Homo sapiens 24-37 11156247-7 2000 Treatment with paclitaxel and C225 down-regulated the expression of basic fibroblast growth factor, vascular endothelial cell growth factor, interleukin-8, and matrix metalloproteinase type 9 and inhibited tumor-induced neovascularity compared with untreated controls (P < 0.005). Paclitaxel 15-25 C-X-C motif chemokine ligand 8 Homo sapiens 141-154 14698135-13 2004 In the every 3-week paclitaxel group, increase in IL-8 level correlated positively with flu-like symptom (p=0.008). Paclitaxel 20-30 C-X-C motif chemokine ligand 8 Homo sapiens 50-54 11180086-0 2001 Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy. Paclitaxel 78-88 C-X-C motif chemokine ligand 8 Homo sapiens 0-13 11180086-1 2001 BACKGROUND: Paclitaxel has been described to induce interleukin-8 (IL-8) transcription and secretion in human ovarian carcinoma cells. Paclitaxel 12-22 C-X-C motif chemokine ligand 8 Homo sapiens 52-65 11180086-1 2001 BACKGROUND: Paclitaxel has been described to induce interleukin-8 (IL-8) transcription and secretion in human ovarian carcinoma cells. Paclitaxel 12-22 C-X-C motif chemokine ligand 8 Homo sapiens 67-71 11180086-2 2001 The objective of this study was to investigate possible clinical implications of the effect of paclitaxel on IL-8 serum levels in patients suffering from ovarian carcinoma. Paclitaxel 95-105 C-X-C motif chemokine ligand 8 Homo sapiens 109-113 11180086-12 2001 CONCLUSIONS: The authors found a significant decrease in IL-8 serum levels in patients undergoing a paclitaxel-containing chemotherapy regimen, indicating that IL-8 possibly acts as a useful monitoring marker in patients with ovarian carcinoma. Paclitaxel 100-110 C-X-C motif chemokine ligand 8 Homo sapiens 57-61 11180086-12 2001 CONCLUSIONS: The authors found a significant decrease in IL-8 serum levels in patients undergoing a paclitaxel-containing chemotherapy regimen, indicating that IL-8 possibly acts as a useful monitoring marker in patients with ovarian carcinoma. Paclitaxel 100-110 C-X-C motif chemokine ligand 8 Homo sapiens 160-164 15823106-0 2005 Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens. Paclitaxel 87-97 C-X-C motif chemokine ligand 8 Homo sapiens 26-39 15823106-1 2005 Previous findings showed that paclitaxel induces interleukin-8 (IL-8) transcription and secretion in ovarian cancer cells in vitro. Paclitaxel 30-40 C-X-C motif chemokine ligand 8 Homo sapiens 49-62 15823106-1 2005 Previous findings showed that paclitaxel induces interleukin-8 (IL-8) transcription and secretion in ovarian cancer cells in vitro. Paclitaxel 30-40 C-X-C motif chemokine ligand 8 Homo sapiens 64-68 15823106-2 2005 We hypothesized that paclitaxel treatment, which is a standard care for ovarian cancer patients, may increase the secretion of IL-8, resulting in the elevated serum IL-8 levels. Paclitaxel 21-31 C-X-C motif chemokine ligand 8 Homo sapiens 127-131 15823106-2 2005 We hypothesized that paclitaxel treatment, which is a standard care for ovarian cancer patients, may increase the secretion of IL-8, resulting in the elevated serum IL-8 levels. Paclitaxel 21-31 C-X-C motif chemokine ligand 8 Homo sapiens 165-169 15823106-3 2005 In this study, we investigated the relationship between paclitaxel exposure and IL-8 levels of an ovarian and a breast carcinoma cell line in vitro and serums of patients with ovarian carcinoma. Paclitaxel 56-66 C-X-C motif chemokine ligand 8 Homo sapiens 80-84 15823106-5 2005 However, supernatant levels of IL-8 assessed by enzyme-linked immunosorbent assay before and after treatment with different concentrations of paclitaxel were significantly lower in MCF-7 than in MDAH 2774. Paclitaxel 142-152 C-X-C motif chemokine ligand 8 Homo sapiens 31-35 15823106-8 2005 The basal level of IL-8 after paclitaxel-containing treatment was found to be significantly higher in the serums of patients who had high tumor burden than in patients who had optimal debulking surgery and low tumor burden. Paclitaxel 30-40 C-X-C motif chemokine ligand 8 Homo sapiens 19-23 15823106-9 2005 These data strongly suggest that IL-8 may be an important predictive marker for tumor volume as well as sensitivity to paclitaxel. Paclitaxel 119-129 C-X-C motif chemokine ligand 8 Homo sapiens 33-37 12027404-13 2002 In summary, while both IL-6 and IL-8 are overexpressed in paclitaxel resistant cell lines, only IL-6 has the potential to contribute directly to paclitaxel and doxorubicin resistance in U-2OS. Paclitaxel 58-68 C-X-C motif chemokine ligand 8 Homo sapiens 32-36 10823417-0 2000 Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-kappaB- and AP-1-dependent mechanism. Paclitaxel 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 24-37 10823417-4 2000 In this report, we demonstrate that a subset of human lung carcinoma cell lines respond to paclitaxel treatment with an up to a fivefold increase in the production of interleukin-8 (IL-8). Paclitaxel 91-101 C-X-C motif chemokine ligand 8 Homo sapiens 167-180 9523735-2 1998 In addition to its cytotoxic effects on ovarian cancer cells, taxol can transcriptionally activate genes such as IL-8 that may play a role in tumorigenesis. Paclitaxel 62-67 C-X-C motif chemokine ligand 8 Homo sapiens 113-117 10679119-2 2000 Our laboratory has shown that paclitaxel induces IL-8, a member of the C-X-C family of chemokines, in subsets of human ovarian cancer cells. Paclitaxel 30-40 C-X-C motif chemokine ligand 8 Homo sapiens 49-53 10589757-0 1999 Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Paclitaxel 60-70 C-X-C motif chemokine ligand 8 Homo sapiens 143-147 10589757-0 1999 Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Paclitaxel 191-201 C-X-C motif chemokine ligand 8 Homo sapiens 143-147 10823417-4 2000 In this report, we demonstrate that a subset of human lung carcinoma cell lines respond to paclitaxel treatment with an up to a fivefold increase in the production of interleukin-8 (IL-8). Paclitaxel 91-101 C-X-C motif chemokine ligand 8 Homo sapiens 182-186 10823417-6 2000 Increased IL-8 mRNA is seen as early as 45 min with a peak at 4 h after paclitaxel treatment. Paclitaxel 72-82 C-X-C motif chemokine ligand 8 Homo sapiens 10-14 11240649-0 2000 Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Paclitaxel 149-159 C-X-C motif chemokine ligand 8 Homo sapiens 32-36 11240649-10 2000 Treatment with paclitaxel is associated with an increase in expression of a limited number of cytokines in patients with ovarian cancer, notably IL-6, IL-8 and MCP-1. Paclitaxel 15-25 C-X-C motif chemokine ligand 8 Homo sapiens 151-155 9774447-2 1998 We reported previously that paclitaxel can induce interleukin (IL)-8 promoter activation in subgroups of ovarian cancer through the activation of both AP-1 and nuclear factor kappaB. Paclitaxel 28-38 C-X-C motif chemokine ligand 8 Homo sapiens 50-68 9774447-3 1998 Further analysis of paclitaxel analogs indicates that the degree of IL-8 induction by analysis correlates with the extent of cell death; however, IL-8 itself is not the cause of cell death. Paclitaxel 20-30 C-X-C motif chemokine ligand 8 Homo sapiens 68-72 9774447-8 1998 Paclitaxel-induced IL-8 promoter activation was inhibited by dominant-inhibitory mutants of JNK, p38, and the super-repressor form of IkappaBalpha, but not by dominant-inhibitory forms of ERK1. Paclitaxel 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 19-23 9558006-4 1998 Here, we present research examining paclitaxel"s ability to alter expression of the interleukin-1beta (IL-1beta) and IL-8 cytokines in primary human monocytes, T lymphocytes, and four human breast cancer cell lines: MCF-7, ZR-75-1, MDA-MB-468, and MDA-MB-231. Paclitaxel 36-46 C-X-C motif chemokine ligand 8 Homo sapiens 117-121 9523735-6 1998 Some of the taxol analogs modified at positions C-1 and/or C-2 with increased hydrophobicity induced IL-8 expression more than threefold over that induced by taxol or taxotere and more than 20-fold over control cells. Paclitaxel 12-17 C-X-C motif chemokine ligand 8 Homo sapiens 101-105 9523735-6 1998 Some of the taxol analogs modified at positions C-1 and/or C-2 with increased hydrophobicity induced IL-8 expression more than threefold over that induced by taxol or taxotere and more than 20-fold over control cells. Paclitaxel 158-163 C-X-C motif chemokine ligand 8 Homo sapiens 101-105 9271387-0 1997 Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter. Paclitaxel 33-43 C-X-C motif chemokine ligand 8 Homo sapiens 90-103 9271387-0 1997 Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter. Paclitaxel 45-50 C-X-C motif chemokine ligand 8 Homo sapiens 90-103 9271387-3 1997 Previously, we demonstrated that paclitaxel can induce interleukin-8 (IL-8) gene expression at the transcriptional level in subsets of human ovarian cancer lines. Paclitaxel 33-43 C-X-C motif chemokine ligand 8 Homo sapiens 55-68 9271387-3 1997 Previously, we demonstrated that paclitaxel can induce interleukin-8 (IL-8) gene expression at the transcriptional level in subsets of human ovarian cancer lines. Paclitaxel 33-43 C-X-C motif chemokine ligand 8 Homo sapiens 70-74 9271387-6 1997 Paclitaxel only activated the IL-8 promoter in responsive cells. Paclitaxel 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 30-34 9271387-7 1997 The AP-1 and NF-kappaB binding sites in the IL-8 promoter are required for activation by paclitaxel; in contrast, a C/EBP site required for IL-8 promoter activation in other cell types is not involved. Paclitaxel 89-99 C-X-C motif chemokine ligand 8 Homo sapiens 44-48 9271387-10 1997 These results demonstrate a molecular mechanism for cell-specific paclitaxel-induced IL-8 gene expression which may have clinical relevance. Paclitaxel 66-76 C-X-C motif chemokine ligand 8 Homo sapiens 85-89 29486738-10 2018 IL-6, IL-8 and XIAP showed increased expressions in PTX-treated cells and this over-production effect was inhibited in TLR4-transient knockdown cells. Paclitaxel 52-55 C-X-C motif chemokine ligand 8 Homo sapiens 6-10 8543832-5 1996 This IL-8 gene expression was inhibited by pretreatment with 5 microM taxol, a microtubule-stabilizing agent. Paclitaxel 70-75 C-X-C motif chemokine ligand 8 Homo sapiens 5-9 8543832-6 1996 Colchicine or vinblastine, microtubule-disrupting agents, induced IL-8 gene expression, which was also inhibited by taxol treatment. Paclitaxel 116-121 C-X-C motif chemokine ligand 8 Homo sapiens 66-70 34284965-13 2022 CONCLUSION: Our work demonstrated that CXCL8 may be a potential molecule to be targeted for the treatment of PTX-resistant TNBC. Paclitaxel 109-112 C-X-C motif chemokine ligand 8 Homo sapiens 39-44 32815403-9 2020 Paclitaxel exposure reduced IL-8 levels in cancer cell lines, whilst no cytotoxic effect was observed in all cell lines at treatment concentration levels (<= 0.1% (w/v) paclitaxel in silicone). Paclitaxel 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 28-32 8640818-0 1996 Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Paclitaxel 0-5 C-X-C motif chemokine ligand 8 Homo sapiens 46-50 8640818-4 1996 Taxol induced secretion of interleukin (IL) 8 but not IL-6, IL-1alpha, or IL-1beta in 4 of 10 samples. Paclitaxel 0-5 C-X-C motif chemokine ligand 8 Homo sapiens 27-45 34284965-0 2022 CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers. Paclitaxel 35-45 C-X-C motif chemokine ligand 8 Homo sapiens 0-5 34284965-1 2022 BACKGROUND: This study aimed to demonstrate CXCL8 expression in TNBC tissues and cells, and elucidate the functional mechanism of CXCL8 in paclitaxel (PTX)-resistant TNBC. Paclitaxel 139-149 C-X-C motif chemokine ligand 8 Homo sapiens 44-49 34284965-1 2022 BACKGROUND: This study aimed to demonstrate CXCL8 expression in TNBC tissues and cells, and elucidate the functional mechanism of CXCL8 in paclitaxel (PTX)-resistant TNBC. Paclitaxel 139-149 C-X-C motif chemokine ligand 8 Homo sapiens 130-135 34284965-1 2022 BACKGROUND: This study aimed to demonstrate CXCL8 expression in TNBC tissues and cells, and elucidate the functional mechanism of CXCL8 in paclitaxel (PTX)-resistant TNBC. Paclitaxel 151-154 C-X-C motif chemokine ligand 8 Homo sapiens 44-49 34284965-1 2022 BACKGROUND: This study aimed to demonstrate CXCL8 expression in TNBC tissues and cells, and elucidate the functional mechanism of CXCL8 in paclitaxel (PTX)-resistant TNBC. Paclitaxel 151-154 C-X-C motif chemokine ligand 8 Homo sapiens 130-135 34284965-5 2022 The protein expression and distribution of CXCL8 were examined by immunohistochemistry, MTT assay and colony formation assay were performed to determine cell viability of TNBC cells treated with PTX. Paclitaxel 195-198 C-X-C motif chemokine ligand 8 Homo sapiens 43-48 34284965-10 2022 CXCL8 was upregulated in PTX-resistant TNBC cells. Paclitaxel 25-28 C-X-C motif chemokine ligand 8 Homo sapiens 0-5 34284965-11 2022 Knockdown of CXCL8 increased the sensitivity of TNBC cells to PTX. Paclitaxel 62-65 C-X-C motif chemokine ligand 8 Homo sapiens 13-18 34284965-12 2022 Mechanically, CXCL8 deficiency regulated PTX resistance in TNBC cells via cell apoptosis signaling pathway. Paclitaxel 41-44 C-X-C motif chemokine ligand 8 Homo sapiens 14-19 35163066-4 2022 In the present study, we demonstrated, by using both primary epidermal keratinocytes (NHEK) and a 3D epidermis model, that paclitaxel impairs different cellular processes: paclitaxel increased the release of IL-1alpha, IL-6, and IL-8 inflammatory cytokines, produced reactive oxygen species (ROS) release and apoptosis, and reduced the endothelial tube formation in the dermal microvascular endothelial cells (HDMEC). Paclitaxel 123-133 C-X-C motif chemokine ligand 8 Homo sapiens 229-233 35163066-4 2022 In the present study, we demonstrated, by using both primary epidermal keratinocytes (NHEK) and a 3D epidermis model, that paclitaxel impairs different cellular processes: paclitaxel increased the release of IL-1alpha, IL-6, and IL-8 inflammatory cytokines, produced reactive oxygen species (ROS) release and apoptosis, and reduced the endothelial tube formation in the dermal microvascular endothelial cells (HDMEC). Paclitaxel 172-182 C-X-C motif chemokine ligand 8 Homo sapiens 229-233 29486738-14 2018 CONCLUSIONS: The acquired TLR4-mediated PTX resistance in BCA and melanoma is explained partly by the paracrine effect of IL-6 and IL-8 released into the tumor microenvironment and over-production of anti-apoptotic protein, XIAP, in BCA cells and importantly CpdA could reduce this effect and sensitize PTX-induced apoptosis in a synergistic manner. Paclitaxel 40-43 C-X-C motif chemokine ligand 8 Homo sapiens 131-135 26282378-0 2015 Induction of oxidative stress by Taxol vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring de novo synthesis of mRNA. Paclitaxel 33-38 C-X-C motif chemokine ligand 8 Homo sapiens 84-97 27262815-7 2016 Moreover, PFKFB3 modulated toll like receptor 4 (TLR4) and MyD88 expression as well as interleukin (IL)-6 and IL-8 release from breast cancer cells in response to paclitaxel exposure. Paclitaxel 163-173 C-X-C motif chemokine ligand 8 Homo sapiens 110-114 24527095-8 2014 It was found that lipopolysaccharide and Pac significantly increase the secretion of IL-6 and IL-8 in the SKOV3 cell line. Paclitaxel 41-44 C-X-C motif chemokine ligand 8 Homo sapiens 94-98 25521357-0 2014 Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. Paclitaxel 119-129 C-X-C motif chemokine ligand 8 Homo sapiens 52-56 25175786-8 2014 Following the paclitaxel treatment, a decreased apoptosis and G2 phase ratio, an increased cell migration ratio, and an increased production of IL-8 were found in MyD88-overexpressed A549 cells. Paclitaxel 14-24 C-X-C motif chemokine ligand 8 Homo sapiens 144-148 24527095-9 2014 Similarly, Pac resulted in a significant upregulation of IL-6 and IL-8 in OVCAR3 cells, but not in A2780 and 3AO cells. Paclitaxel 11-14 C-X-C motif chemokine ligand 8 Homo sapiens 66-70 22923236-6 2012 Neutralizing antibodies against IL-6 and IL-8 partially reversed the drug resistance of MCF-7/R to paclitaxel and doxorubicin, while a neutralizing antibody against MCP-1 had no significant effect. Paclitaxel 99-109 C-X-C motif chemokine ligand 8 Homo sapiens 41-45 23391723-7 2013 The TGF-beta type I receptor kinase inhibitor LY2157299, a neutralizing TGF-beta type II receptor antibody, and SMAD4 siRNA all blocked paclitaxel-induced IL8 transcription and CSC expansion. Paclitaxel 136-146 C-X-C motif chemokine ligand 8 Homo sapiens 155-158 22743248-7 2012 We demonstrated that treatment of A375 cells with IS in combination with paclitaxel resulted in a significant decrease in the production of IL-8 and VEGF, compared with paclitaxel alone. Paclitaxel 73-83 C-X-C motif chemokine ligand 8 Homo sapiens 140-144